A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

Key facts

Sponsor

Forma Therapeutics, Inc.

Principal Investigator

Clinical Transparency (dept. 2834)

Novo Nordisk A/S

Intervention

Etavopivat Tablets Low dose(drug)

Enrollment

450 enrolled

Eligibility

12-65 years · All sexes

Timeline

2021 – 2027

Study locations (30)

• Univ of Alabama Birmingham, Birmingham, Alabama, United States
• Phoenix Children's Hsptl, Phoenix, Arizona, United States
• [Legal] Woodland International Research Group, LLC, Little Rock, Arkansas, United States
• [Legal] Collaborative Neuroscience Network, LLC, Long Beach, California, United States
• Pacific Research Partners, Oakland, California, United States
• UCSF Oakland Benioff ChildHosp, Oakland, California, United States
• University Of California Irvine, Orange, California, United States
• UC Davis Medical Center, Sacramento, California, United States
• University of Connecticut, Farmington, Connecticut, United States
• Yale University, New Haven, Connecticut, United States
• Children's National Health Hospital, Washington D.C., District of Columbia, United States
• Howard University, Washington D.C., District of Columbia, United States
• Cornerstone Research Institute, Altamonte Springs, Florida, United States
• University of Florida, Gainesville, Florida, United States
• Foundation for Sickle Cell Disease Research, Hollywood, Florida, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

This study is currently undergoing a sponsor transition from Forma to Novo Nordisk. Sponsor field will be updated once the transition is complete.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Genetic hemoglobinopathy

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07488091
  Multi Disciplinary Sickle Cell Disease Obstetrics Care Program in Ghana
  University of Ghana Medical School
• RECRUITINGNANCT07316478
  Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease
  University of Pennsylvania
• RECRUITINGNANCT07188766
  Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis
  Imam Abdulrahman Bin Faisal University
• RECRUITINGNANCT07090668
  Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease
  Emory University
• RECRUITINGPHASE1NCT07087262
  A Phase I Study of SNH-119014 in Healthy Volunteers
  ScinnoHub Pharmaceutical Co., Ltd.
• RECRUITINGNANCT06886477
  Sickle Cell, Pain and Mediterranean Diet
  University of Illinois at Chicago
• RECRUITINGNANCT06367192
  School Readiness Intervention for Preschool Children With Sickle Cell Disease
  St. Jude Children's Research Hospital
• RECRUITINGNANCT06735625
  Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"
  Centre Hospitalier de Saint-Denis

See all trials for Genetic hemoglobinopathy →